Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency.
Gibson
K M
KM
Baylor Research Institute, Dallas, Texas, USA.
Jakobs
C
C
Ogier
H
H
Hagenfeldt
L
L
Eeg-Olofsson
K E
KE
Eeg-Olofsson
O
O
Aksu
F
F
Weber
H P
HP
Rossier
E
E
Vollmer
B
B
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000445:Aldehyde Oxidoreductases / Q000172:deficiency*; D001928:Brain Diseases, Metabolic / Q000150:complications / Q000188:drug therapy; D018756:GABA Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000150:complications / Q000188:drug therapy*; D012640:Seizures / Q000139:chemically induced; D012978:Sodium Oxybate / Q000134:cerebrospinal fluid; D050644:Succinate-Semialdehyde Dehydrogenase; D016896:Treatment Outcome; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000627:therapeutic use
D018756:GABA Antagonists; D005680:gamma-Aminobutyric Acid; D012978:Sodium Oxybate; D000445:Aldehyde Oxidoreductases; C493643:ALDH5A1 protein, human; D050644:Succinate-Semialdehyde Dehydrogenase; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin